Vertex Pharmaceuticals Inc. said collaborator GlaxoSmithKline plc is likely to file for approval of the HIV protease inhibitor GW433908 - which last month entered its third pivotal Phase III trial - by the end of the year in the U.S. and Europe. (BioWorld Today) Read More
